Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229529 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30229718 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL27749256 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL18795729 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL24899350 | 0.94 | MDM2 (0.47) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL16100914 | 0.89 | MDM4 (0.54) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL16100911 | 0.89 | MDM4 (0.54) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL850472 | 0.89 | CASP3 (0.50) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL31671078 | 0.89 | MDM4 (0.46) | MDM4TP53CASP3MDM2 | |
| SCHEMBL377537 | 0.87 | MDM4 (0.49) | MDM4TP53CASP3MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| US-20240360178-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-110366556-B | Antibacterial peptide macrocyclic compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-3388444-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2018-10-17 | — | — | EP | disclosed |
| EP-3368544-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017072062-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| US-20080287346-A1 | Bioactive peptides | SVENDSEN JOHN SIGURD | 2008-11-20 | — | — | US | disclosed |
| US-7439228-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1009/4885TP53 127/4885CASP3 1714/4885 |
| US-20080287346-A1 | Bioactive peptides | VIP, NGLY1, IAPP | MDM4 425/4885TP53 42/4885CASP3 14/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885CASP3 1570/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MDM4 2686/4885TP53 428/4885CASP3 1567/4885 |
| US-20240360178-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885CASP3 1798/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1149/4885TP53 154/4885CASP3 1646/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885CASP3 1798/4885 |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885CASP3 1570/4885 |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | VIP, ARG1, CX3CR1 | MDM4 3771/4885TP53 3724/4885CASP3 1570/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | MDM4 314/4885TP53 12/4885CASP3 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.